Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(RULE 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant þ

Filed by a Party other than the Registrant o

Check the appropriate box:

o Preliminary Proxy Statement

o Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))

o Definitive Proxy Statement

þ Definitive Additional Materials

o Soliciting Material under Rule 14a-12

Anavex Life Sciences Corp.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

þ No fee required

o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

o Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

SUPPLEMENT TO DEFINITIVE PROXY STATEMENT

The following disclosure supplements the definitive proxy statement filed by Anavex Life Sciences Corp. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on March 10, 2017 (the “Definitive Proxy Statement”). This supplemental information should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety. The information set forth in the Definitive Proxy Statement remains unchanged and is incorporated herein by reference as relevant to the items set forth below.

On March 10, 2017, the Company mailed the letter attached hereto as Attachment 1 to its stockholders, along with the Definitive Proxy Statement and documents ancillary thereto.

Supplemental Information Regarding Proposal 2, the Amendment of the Company’s Articles of Incorporation to Authorize up to 10,000,000 Shares of Blank-Check Preferred Stock

At our 2017 Annual Meeting of Stockholders, to be held on Tuesday, April 18, 2017, our stockholders will vote on an amendment to amend the Company’s Articles of Incorporation to authorize up to 10,000,000 shares of blank-check preferred stock. The Definitive Proxy Statement is amended to add Exhibit A to the Definitive Proxy Statement, which was originally included in the preliminary Proxy Statement filed on February 27, 2017 with the Securities and Exchange Commission. All other items of the Proxy Statement are incorporated herein by reference without changes.

The Board unanimously recommends a vote “FOR” approval of Proposal 2.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to Be Held on Tuesday, April 18, 2017 at the offices of Nasdaq MarketSite at 4 Times Square, New York, NY 10036.

Copies of this proxy statement and proxy materials ancillary hereto, and the 2016 Annual Report may be found on our website at www.anavex.com and at www.proxyvote.com .

Dea r Sha r eho l de r,

I a m p l ea s e d to i nv ite yo u to a tt en d ou r 201 7 Annua l G ene r a l M ee ti n g o f S t o ck ho l de rs (t h e “ M ee ti ng ”), wh i c h w ill b e he ld o n Tuesday , Ap ril 18 , 2017 , 10 : 0 0 a . m ., l o c a l ti m e , a t t h e o ffic e s o f Nasda q M a r ke t S it e , 4 T i m e s Squa r e , Ne w Yo r k , N Y 1003 6 .

You r pa rti c i pa ti o n in t h is m e e ti n g is ve ry i m po rt an t an d w e as k t ha t yo u r ev i e w t h e en cl o s e d p r ox y s t a t e m en t, wh i c h g i ve s i m po rt an t i n f o r m a ti o n r ega r d i n g t h e bus i nes s to b e condu ct e d at t h e M ee ti ng . You r vo te is ve ry i m po rt an t to u s an d w e s tr ong ly encou r ag e yo u to exe r c i s e you r ri gh t to vo te o n t h e m a tt e rs se t f o rth in t h e p r ox y s t a t e m en t. O u r Boa rd o f D ir ec t o rs unan i m ous ly r eco mm end s t ha t yo u vo te in f avo r o f a ll o f t h e p r opo s e d r eso l u ti ons .

Yo u ca n vo te us i n g an y on e o f t h e f o ll ow i n g m e t hod s:

E l ec tr on i ca lly b y sub m itti n g you r vo te a t www . p r oxyvo t e . co m us i n g t h e con tr o l nu m ber fr o m t h e en cl o s e d p r ox y c a r d .

B y t e l ephon e b y ca lli n g 1 - 800 - 690 - 6903 . P l eas e hav e you r p r ox y ca rd ava il ab l e .

B y M a il b y s i gn i n g an d r e t u r n i n g t h e p r ox y ca rd p r ov i de d he r e in as soo n a s poss i b l e .

Th e p r ox y ca rd m us t b e r ece i ve d n o l a t e r t ha n Ap ril 14 , 2017 . P l eas e a ll o w adequa te ti m e f o r m a ili ng .

In Pe rs o n S t ockho l de rs o f r eco rd an d bene fi c i a l s t ockho l de rs w ith sha r e s he ld b y a ban k, b r oke r o r o t he r no m i ne e m a y vo te in pe rs o n a t t h e M ee ti ng . P l ea se no t e , howeve r, t ha t if you r sha r e s a re he ld b y a b r oke r, ban k o r o t he r no m i ne e an d yo u w ish to vo te a t t h e M ee ti ng , yo u w ill no t b e pe r m itt e d to vo te in pe rs o n a t t h e M ee ti n g un l e ss yo u first ob t a in a l ega l p r ox y iss ue d in you r na m e fr o m t h e r e c o rd ho l de r.

Fo r add iti ona l vo ti n g ass i s t anc e o r ques ti ons , p l eas e ca ll ou r p r ox y so li c it a ti o n agen t, K i ngsda le Adv i so rs b y t e l ephon e a t 1 - 800 - 775 - 315 9 o r t h r oug h e m a il at con t ac t us @ k i ngsda l eadv is o rs.c o m .

O n beha lf o f Anavex , t han k yo u f o r you r suppo rt a s sha r eho l de r s . W e l oo k f o r wa rd to bu il d i n g o n ou r pas t acco m p li sh m en ts w ith you r con ti nue d suppo rt, an d w e t han k yo u in advanc e f o r you r vo t e .